Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STE 
STERIS plc (STE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: STE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $272.38
1 Year Target Price $272.38
| 3 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.53% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.61B USD | Price to earnings Ratio 38.18 | 1Y Target Price 272.38 |
Price to earnings Ratio 38.18 | 1Y Target Price 272.38 | ||
Volume (30-day avg) 10 | Beta 0.95 | 52 Weeks Range 199.47 - 253.00 | Updated Date 09/15/2025 |
52 Weeks Range 199.47 - 253.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) 0.91% | Basic EPS (TTM) 6.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.61% | Operating Margin (TTM) 17.85% |
Management Effectiveness
Return on Assets (TTM) 6.22% | Return on Equity (TTM) 9.74% |
Valuation
Trailing PE 38.18 | Forward PE 24.69 | Enterprise Value 26400032627 | Price to Sales(TTM) 4.42 |
Enterprise Value 26400032627 | Price to Sales(TTM) 4.42 | ||
Enterprise Value to Revenue 4.74 | Enterprise Value to EBITDA 18.76 | Shares Outstanding 98490600 | Shares Floating 98093689 |
Shares Outstanding 98490600 | Shares Floating 98093689 | ||
Percent Insiders 0.3 | Percent Institutions 97.19 |
Upturn AI SWOT
STERIS plc
Company Overview
History and Background
STERIS plc (STE) was founded in 1985 as Innovative Medical Technologies, Inc., later becoming STERIS Corporation. It evolved through acquisitions and organic growth, focusing on infection prevention, contamination control, and surgical support systems. Significant milestones include strategic acquisitions expanding product lines and global reach.
Core Business Areas
- Healthcare: Provides sterilization, cleaning, and infection control products and services for hospitals, clinics, and other healthcare facilities.
- Applied Sterilization Technologies: Offers contract sterilization and lab services, primarily using gamma, electron beam, and ethylene oxide technologies, to medical device and pharmaceutical manufacturers.
- Life Sciences: Delivers equipment, consumables, and services for pharmaceutical, research, and biopharmaceutical companies, including sterilization, cleaning, and contamination control solutions.
Leadership and Structure
The leadership team consists of Dan Carestio (President & CEO), Michael J. Dengler (Sr. VP & CFO) and a board of directors. The organizational structure is based on the core business areas.
Top Products and Market Share
Key Offerings
- Steam Sterilizers: Used in hospitals and labs to sterilize medical instruments and equipment. STERIS has a significant market share in North America. Competitors include Getinge and Belimed.
- VHP Biodecontamination Units: Utilized in pharmaceutical and life science facilities for surface decontamination. STERIS is a market leader in this space. Competitors include Bioquell (Ecolab) and ClorDiSys Solutions.
- Consumables (e.g., detergents, sterilants): Recurring revenue stream derived from the use of STERIS's equipment and services. Key competitors include Ecolab and Cantel Medical (now part of Cantel).
Market Dynamics
Industry Overview
The infection prevention and sterilization market is driven by increasing healthcare spending, stringent regulatory requirements, and rising awareness of healthcare-associated infections (HAIs).
Positioning
STERIS plc is a leading player in the infection prevention and sterilization market, with a comprehensive portfolio of products and services, a strong global presence, and a reputation for quality and innovation.
Total Addressable Market (TAM)
The global sterilization services market is projected to reach $15.5 billion by 2028. STERIS is positioned to capitalize on this growth through its established market presence, product portfolio, and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong market position
- Diverse product portfolio
- Recurring revenue streams
- Global presence
- Strong brand reputation
Weaknesses
- Dependence on healthcare spending
- Exposure to regulatory changes
- Integration risks from acquisitions
- High valuation
Opportunities
- Expansion into emerging markets
- Increased outsourcing of sterilization services
- Development of innovative products and technologies
- Growing demand for infection prevention solutions
Threats
- Intense competition
- Pricing pressure
- Economic downturn
- Product liability claims
- Disruptive new technologies
Competitors and Market Share
Key Competitors
- Getinge AB (GETI-B.ST)
- Ecolab Inc. (ECL)
- Cantel Medical (now part of Cantel, no US listing)
Competitive Landscape
STERIS has a strong competitive position due to its comprehensive product portfolio, global presence, and strong brand reputation. However, it faces competition from other large players and smaller niche companies.
Major Acquisitions
Key Surgical
- Year: 2020
- Acquisition Price (USD millions): 850
- Strategic Rationale: Expanded STERIS's portfolio of consumable products and services for the healthcare market.
Growth Trajectory and Initiatives
Historical Growth: STERIS has a history of consistent revenue and earnings growth, both organically and through acquisitions.
Future Projections: Analysts expect STERIS to continue growing its revenue and earnings at a moderate pace, driven by favorable industry trends and strategic initiatives. The average analyst revenue forecast for 2024 is 5518000000
Recent Initiatives: Recent strategic initiatives include acquisitions of businesses that complement STERIS's existing portfolio and investments in new product development.
Summary
STERIS plc is a strong company with a leading position in the infection prevention and sterilization market. Its diverse portfolio, recurring revenue streams, and global presence contribute to its stability. Key areas to watch include regulatory changes, integration of acquisitions, and competitive pressures. STERIS fundamentals continue to look strong.
Peer Comparison
Sources and Disclaimers
Data Sources:
- STERIS plc Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own due diligence and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STERIS plc
Exchange NYSE | Headquaters Mentor, OH, United States | ||
IPO Launch date 1992-06-01 | President, CEO & Director Mr. Daniel A. Carestio | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17787 | Website https://www.steris.com |
Full time employees 17787 | Website https://www.steris.com | ||
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.